Overeating and starving both damage the liver: Cavefish provide new insight into fatty liver disease
Fatty liver, which can lead to liver damage and disease, can occur from both overeating and starvation. Now, new research shows how naturally starvation-resistant cavefish, unlike other animals, are able to protect their liver and remain healthy. The findings have implications for understanding and potentially addressing liver conditions in humans. Researchers from the Stowers Institute […]
Semaglutide Cuts Liver Disease Severity in People With HIV
DENVER — Semaglutide (Ozempic) reduced the amount of liver fat by nearly a third in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), the open-label phase IIb SLIM LIVER study showed. In the single-arm trial, the absolute change in intrahepatic triglyceride (IHTG) content across all participants was -4.2% (95% CI -5.4 to -3.1, […]
Obesity disrupts normal liver function in mice
Your liver plays a vital role in your metabolism, the biological process which converts food into energy. We know that being overweight can negatively affect metabolic activity, but not exactly how. To better understand this, researchers compared the livers of mice which were a typical weight with mice which were obese. They were surprised to […]
New Standard for Unresectable Hepatocellular Carcinoma?
SAN FRANCISCO — After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed. Patients who received durvalumab (Imfinzi) plus bevacizumab (Avastin) in addition to TACE had a median progression-free survival (PFS) of 15.0 months as compared with 8.2 months for TACE […]
5 Things You Should Know About How Alcohol Affects Your Body
Alcohol can affect your body quickly. Getty Within 20 minutes, your liver starts to process the alcohol consumed. However, varying factors like body composition, sex and rate of consumption can determine how quickly you start to feel the effects. In the early stages of drinking, reaction times may be slower and the brain increases production […]
Cancer Risk in NAFLD Higher With Early Disease Onset
The risk for cancer in patients with nonalcoholic fatty liver disease (NAFLD) was highest among those with early-onset disease and declined at later ages of diagnosis, a matched cohort study found. Examining more than 60,000 participants from a prospective Chinese dataset revealed that the increased risk of malignancy with NAFLD was highest among patients diagnosed […]
Transplant May Be Reasonable for Certain CRC Patients With Liver Mets
For a select group of patients with colorectal cancer and unresectable liver metastases, liver transplant may be a reasonable option, according to results from a prospective, nonrandomized controlled cohort study. Overall, among 61 patients who underwent liver transplant, the median disease-free survival (DFS) was 11.8 months (95% CI 9.3-14.2), with a 5-year DFS rate of […]
NAFLD and T2DM Bodes Higher Risk of Liver Decompensation, Cancer
Patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes may be at significantly higher risk of hepatic decompensation and liver cancer, researchers reported. In a meta-analysis of six studies that included 1,737 patients with NAFLD followed for approximately 3 years, those with diabetes had twice the risk for developing hepatic decompensation (HR 2.15, […]
‘Game Changer’ in NASH: Resmetirom Hits Endpoints in Pivotal Study
VIENNA — The investigational agent resmetirom resolved liver biopsy findings in nonalcoholic steatohepatitis (NASH) more often than placebo, according to the phase III MAESTRO-NASH trial. While 10% of placebo patients achieved resolution of inflammation, ballooning, and disease activity, the rate was 26% among people treated with the 80-mg dose of resmetirom and 30% with the […]
Trial Suggests Optimal Approach to Unresectable CRC Liver Mets
For patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI plus bevacizumab (Avastin) was the “preferred” systemic induction regimen for those with a right-sided or RAS- or BRAF V600E-mutated primary tumor, according to a phase III randomized trial. Among these patients, the median progression-free survival (PFS) was 9.0 months in those receiving FOLFOX or FOLFIRI […]